DARZALEX® may help you live longer without your multiple myeloma getting worse
DARZALEX® in combination with Revlimid® (lenalidomide) + dexamethasone (DRd) was proven effective in a clinical study of adults who were newly diagnosed with multiple myeloma and cannot receive a stem cell transplant.*
of patients treated with DARZALEX® + Rd (n=368) lived without their disease getting worse vs 61% of patients treated with Rd alone (n=369).†
†At a median follow-up of 28 months.
More patients responded to DARZALEX® in combination with Rd vs Rd alone
93% of patients responded to DARZALEX® + Rd vs 81% of patients treated with Rd alone.
*The main goals of the study were to measure the length of time patients lived without their multiple myeloma getting worse and how many people responded to treatment.
How DARZALEX® works
DARZALEX® is not chemotherapy. It is an immunotherapy that works with your immune system.
DARZALEX® targets a specific protein on multiple myeloma cells and may also affect normal cells with this protein. DARZALEX® can cause serious side effects, including infusion reactions and decreases in blood cell counts. See Important Safety Information below.
Learn more about how DARZALEX® works.
Please see Important Product Information.